Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy

被引：19
作者：
Chang, Susie
Perry, Julian D.
Kosmorsky, Gregory S.
Braun, William E.
机构：
[1] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA
来源：
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY | 2007年 / 23卷 / 03期
关键词：
D O I：
10.1097/IOP.0b013e3180500d57
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
We report a patient with dysthyroid optic neuropathy refractory to steroids and orbital decompression treated with rapamycin, a fibroblast and T cell inhibitor. Symptoms, visual acuity, color plate testing, and visual fields improved. Aside from hypercholesterolemia, no complication related to this therapy was observed. By addressing the pathogenesis of thyroid eye disease, rapamycin may represent an alternative when standard treatments fail. Further investigation of rapamycin for treatment of dysthyroid orbitopathy is warranted.
引用
收藏
页码：225 / 226
页数：2
相关论文
共 9 条
  • [1] Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: A putative mechanism for T-cell infiltration of the thyroid in autoimmune disease
    Gianoukakis, AG
    Douglas, RS
    King, CS
    Cruikshank, WW
    Smith, TJ
    [J]. ENDOCRINOLOGY, 2006, 147 (04) : 1941 - 1949
  • [2] Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
    Guba, M
    von Breitenbuch, P
    Steinbauer, M
    Koehl, G
    Flegel, S
    Hornung, M
    Bruns, CJ
    Zuelke, C
    Farkas, S
    Anthuber, M
    Jauch, KW
    Geissler, EK
    [J]. NATURE MEDICINE, 2002, 8 (02) : 128 - 135
  • [3] Kazim M, 2002, ARCH OPHTHALMOL-CHIC, V120, P380
  • [4] Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts
    Pritchard, J
    Horst, N
    Cruikshank, W
    Smith, TJ
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (02) : 942 - 950
  • [5] Rapamycin in transplantation: A review of the evidence
    Saunders, RN
    Metcalfe, MS
    Nicholson, ML
    [J]. KIDNEY INTERNATIONAL, 2001, 59 (01) : 3 - 16
  • [6] Rapamune® (RAPA, rapamycin, sirolimus):: Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
    Sehgal, SN
    [J]. CLINICAL BIOCHEMISTRY, 1998, 31 (05) : 335 - 340
  • [7] Stimulation of adipogenesis, peroxisone proliferator-activated receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts
    Valyasevi, RW
    Harteneck, DA
    Dutton, CM
    Bahn, RS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) : 2352 - 2358
  • [8] Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21(ras) activated, AP-1-dependent pathway
    Vrtovsnik, F
    Couette, S
    Prie, D
    Lallemand, D
    Friedlander, G
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (04) : 1016 - 1027
  • [9] Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
    Zhu, JL
    Wu, J
    Frizell, E
    Liu, SL
    Bashey, R
    Rubin, R
    Norton, P
    Zern, MA
    [J]. GASTROENTEROLOGY, 1999, 117 (05) : 1198 - 1204
1